IPP Bureau
Aurigene Pharmaceutical opens biologics facility in Genome Valley, Hyderabad
By IPP Bureau - June 04, 2024
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Merck's oncology pipeline of DDRi and ADC poised to advance cancer treatment
By IPP Bureau - June 04, 2024
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Pfizer’s ADCETRIS regimen produces clinically meaningful improvement in overall survival in patients with DLBCL
By IPP Bureau - June 04, 2024
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
PharmaLytica 2024: India exported US$ 27.8 billion worth of drugs in FY 2023-24
By IPP Bureau - June 03, 2024
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
Supriya Lifescience FY24 PAT up 32%
By IPP Bureau - June 03, 2024
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
NTPC, Tata Memorial Centre launch cancer awareness initiative
By IPP Bureau - June 03, 2024
The cancer screening and awareness camp will run for four months in the Mira Bhayander Region, benefiting approximately 5,000 police personnel
Takeda and Pfizer announce results from Positive Phase 3 HD21 trial of additional ADCETRIS combination in frontline hodgkin lymphoma
By IPP Bureau - June 03, 2024
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Bionova Scientific aims to set up new Plasmid DNA GMP facility neat Houston, US
By IPP Bureau - June 03, 2024
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Sun Pharma to present results of the Phase III PIVOTAL trial of Nidlegy in melanoma at ASCO 2024
By IPP Bureau - June 01, 2024
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Cupid receives vendor approval from Godrej Consumer for Supply of Kamasutra condoms
By IPP Bureau - June 01, 2024
This significant achievement includes an initial order from GCPL valued at a substantial Rs. 2.4 crore
Moderna receives U.S. FDA approval for RSV Vaccine mRESVIA
By IPP Bureau - June 01, 2024
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
AbbVie receives positive CHMP opinion for Risankizumab for treatment ulcerative colitis
By IPP Bureau - June 01, 2024
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
BlueRock Therapeutics receives FDA RMAT designation for Parkinson’s disease cell therapy candidate bemdaneprocel
By IPP Bureau - May 31, 2024
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
Merck inks MoU with KAIST to advance scientific collaboration
By IPP Bureau - May 30, 2024
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
